Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AtoOxy for Obstructive Sleep Apnea
NCT03919955Phase 2Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Sep 2019
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of atomoxetine, oxybutynin in obstructive sleep apnea (OSA), sponsored by Brigham and Women's Hospital. Started Sep 2019; status: completed.
02
Drugs
atomoxetineoxybutynin
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT03919955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03919955.